¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"molecular plexus"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • molecular weight
    ºÐÀÚ·®
  • molecular weight determination
    ºÐÀÚ·®ÃøÁ¤
  • abdominal aortic plexus
    ¹è´ëµ¿¸Æ½Å°æ¾ó±â, º¹ºÎ´ëµ¿¸Æ½Å°æÃÑ
  • Auerbach plexus
    ¾Æ¿ì¾î¹ÙÈå½Å°æ¾ó±â
  • autonomic nerve plexus
    ÀÚÀ²½Å°æ¾ó±â
  • basilar plexus
    ³ú¹Ù´ÚÁ¤¸Æ¾ó±â
  • brachial plexus
    ÆÈ½Å°æ¾ó±â
  • brachial plexus anesthesia
    »ó¿Ï½Å°æÃѸ¶Ãë, À§ÆÈ½Å°æ¾ó±â¸¶Ãë
  • brachial plexus block
    ÆÈ½Å°æ¾ó±âÂ÷´Ü, ÆÈ½Å°æ¾ó±âºí·Ï
  • coccygeal plexus
    ²¿¸®½Å°æ¾ó±â
  • cardiac plexus
    ½ÉÀå½Å°æ¾ó±â
  • carotid plexus
    ¸ñµ¿¸Æ½Å°æ¾ó±â
  • cavernous plexus
    ÇØ¸éÁ¤¸Æ±¼½Å°æ¾ó±â
  • celiac plexus
    º¹°­½Å°æ¾ó±â
  • cervical plexus
    ¸ñ½Å°æ¾ó±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • molecular weight
    ºÐÀÚ·®
  • molecular air pump
    ºÐÀڽİø±âÆßÇÁ
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇа˻ç
  • molecular tumbling rate
    ºÐÀÚÅÒºí¸µ·ü
  • molecular weight modifier
    ºÐÀÚ·®Á¶ÀýÁ¦
  • Auerbach¡¯s plexus
    (¢¡myenteric plexus) ±ÙÀ°Ãþ½Å°æ¾ó±â
  • autonomic nerve plexus
    ÀÚÀ²½Å°æ¾ó±â
  • plexus anesthesia
    ½Å°æ¾ó±â¸¶Ãë
  • basilar plexus
    ³ú¹Ù´ÚÁ¤¸Æ¾ó±â
  • brachial plexus
    ÆÈ½Å°æ¾ó±â
  • brachial plexus block
    ÆÈ½Å°æ¾ó±âÂ÷´Ü¸¶Ãë
  • cardiac plexus
    ½ÉÀå½Å°æ¾ó±â
  • carotid plexus
    ¸ñµ¿¸Æ½Å°æ¾ó±â
  • cavernous plexus
    ÇØ¸éÁ¤¸Æ½Å°æ¾ó±â
  • celiac plexus
    º¹°­½Å°æ¾ó±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • pharyngeal plexus
    ÀενŰæ¾ó±â
  • pharyngeal plexus
    ÀεÎÁ¤¸Æ¾ó±â
  • plexus
    ¾ó±â, ÃÑ(õ¿).
  • plexus anesthesia
    (½Å°æ)ÃѸ¶Ãë(¹ý)(ãêÌèõ¿Ø«ö­Ûö).
  • plexus aorticus abdominalis ³ª
    »À´ëµ¿¸Æ½Å°æ¾ó±â, º¹´ëµ¿¸Æ½Å°æÃÑ(ÜÙÓÞÔÑØæ ãêÌèõ¿).
  • plexus aorticus thoracicus ³ª
    °¡½¿´ëµ¿¸Æ½Å°æ¾ó±â, Èä´ëµ¿¸Æ½Å°æÃÑ(ýØÓÞÔÑ ØæãêÌèõ¿).
  • plexus arteriae cerebri anterioris ³ª
    ¾Õ´ë³úµ¿¸Æ¾ó±â, Àü´ë³úµ¿¸ÆÃÑ(îñÓÞ ÒàÔÑØæõ¿).
  • plexus arteriae cerebri mediae ³ª
    Áß°£´ë³úµ¿¸Æ¾ó±â, Áß´ë³úµ¿¸ÆÃÑ(ñéÓÞÒà ÔÑØæõ¿).
  • plexus arteriae chorioideae ³ª
    ¸Æ¶ô¸·µ¿¸Æ¾ó±â, ¸Æ¶ô¸·µ¿¸ÆÃÑ(ØæÕ©Ø¯ÔÑØæõ¿ ).
  • plexus auricularis posterior ³ª
    µÚ±Ó¹ÙÄû¾ó±â, ÈÄÀ̰³ÃÑ(ý­ì¼Ë¿õ¿).
  • plexus auricularis posterior ³ª
    µÚõ¤aÄû¾ó±â, ÈÄÀ̰³ÃÑ(ý­ì¼Ë¿õ¿).
  • plexus autonomici ³ª
    ÀÚÀ²½Å°æ¾ó±â, ÀÚÀ²½Å°æÃÑ(í»ëÏãêÌèõ¿).
  • plexus basilaris ³ª
    ³ú¹Ù´ÚÁ¤¸Æ¾ó±â, ³úÀúÁ¤¸ÆÃÑ(Òàî¼ð¡Øæõ¿).
  • plexus block
    ½Å°æÃÑÂ÷´Ü.
  • plexus brachialis ³ª
    ÆÈ½Å°æ¾ó±â, ¿Ï½Å°æÃÑ(èÓãêÌèõ¿).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • molecular filter
    ºÐÀڰŸ£°³.
  • molecular force
    ºÐÀÚ·Â(ÝÂí­æ³).
  • molecular form
    ºÐÀÚÇüÅÂ
  • molecular formula
    ºÐÀÚ½Ä(ÝÂí­ãÒ).
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇÐ<ÀÚ>°Ë»ç
  • molecular genetics
    ºÐÀÚÀ¯ÀüÇÐ(¡­ë¶îîùÊ).
  • molecular genetics
    ºÐÀÚÀ¯ÀüÇÐ
  • molecular grating
    ºÐÀÚ°ÝÀÚ(ÝÂí­Ì«í­).
  • molecular heat
    ºÐÀÚ¿­(ÝÂí­æð).
  • molecular hypothesis
    ºÐÀÚ°¡¼³.
  • molecular layer
    ºÐÀÚÃþ(ÝÂí­öµ).
  • molecular layer
    ºÐÀÚÃþ
  • molecular layer plexiform layer
    ºÐÀÚÃþ
  • molecular lesion
    ºÐÀÚº´º¯(¡­Ü»Ü¨).
  • molecular magnet
    ºÐÀÚÀÚ¼®(¡­í¸à´).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Lymphatic plexus
    ¸²ÇÁ°ü¾ó±â
    [¿¾ ¿ë¾î] ÀӯİüÃÑ
  • Lymphatic plexus
    ¸²ÇÁ¾ó±â
    [¿¾ ¿ë¾î] ÀÓÆÄÃÑ
  • Subgemmal nerve plexus
    ¸ÀºÀ¿À¸®¹Ø½Å°æ¾ó±â
    [¿¾ ¿ë¾î] ¹Ì·ÚÇϽŰæÃÑ
  • Vascular plexus
    ¸Æ°ü¾ó±â
    [¿¾ ¿ë¾î] ¸Æ°üÃÑ
  • Perivascular nerve plexus
    ¸Æ°üÁÖÀ§½Å°æ¾ó±â
    [¿¾ ¿ë¾î] Ç÷°üÁÖÀ§½Å°æÃÑ
  • Cranial venous plexus
    ¸Ó¸®Á¤¸Æ¾ó±â
    [¿¾ ¿ë¾î] µÎ°³Á¤¸ÆÃÑ
  • Cervical plexus
    ¸ñ½Å°æ¾ó±â
    [¿¾ ¿ë¾î] °æ½Å°æÃÑ
  • External carotid plexus
    ¹Ù±ù¸ñ½Å°æ¾ó±â
    [¿¾ ¿ë¾î] ¿Ü°æµ¿¸Æ½Å°æÃÑ
  • Vesical plexus
    ¹æ±¤½Å°æ¾ó±â
    [¿¾ ¿ë¾î] ¹æ±¤½Å°æÃÑ
  • Vesical venous plexus
    ¹æ±¤Á¤¸Æ¾ó±â
    [¿¾ ¿ë¾î] ¹æ±¤Á¤¸ÆÃÑ
  • Abdominal aortic plexus
    ¹è´ëµ¿¸Æ½Å°æ¾ó±â
    [¿¾ ¿ë¾î] º¹´ëµ¿¸Æ½Å°æÃÑ
  • Celiac plexus
    º¹°­½Å°æ¾ó±â
    [¿¾ ¿ë¾î] º¹°­½Å°æÃÑ
  • Suprarenal plexus
    ºÎ½Å½Å°æ¾ó±â
    [¿¾ ¿ë¾î] ºÎ½Å½Å°æÃÑ
  • Subclavian plexus
    ºøÀ幨½Å°æ¾ó±â
    [¿¾ ¿ë¾î] ¼â°ñÇϵ¿¸Æ½Å°æÃÑ
  • Subodontoblastic nerve plexus
    »ó¾ÆÁú¸ð¼¼Æ÷¹Ø½Å°æ¾ó±â
    [¿¾ ¿ë¾î] »ó¾ÆÁú¸ð¼¼Æ÷ÇϽŰæÃÑ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • weight-average molecular weight
    ¹«°ÔÆò±Õ(øÁг) ºÐÀÚ·®(ÝÂí­Õá)
  • z-average molecular weight
    z Æò±ÕºÐÀÚ·® (øÁгÝÂí­Õá)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
EMER electromagnetic molecular electron resonance
GMV gram molecular volume
GMW gram molecular weight
HMW high-molecular-weight
HMWC high-molecular-weight component
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CoMFA Comparative Molecular Field Analysis
HMM High molecular mass
HMW High molecular weight
HMWK High molecular weight kininogen
MW High-molecular-weight
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • molecular weight distribution
    ºÐÀÚ·® ºÐÆ÷
  • basilar plexus
    ³ú¹Ù´Ú Á¤¸Æ ¾ó±â, ³úÀú Á¤¸ÆÃÑ
  • brachial plexus avulsion
    »ó¿Ï ½Å°æÃÑ ÀûÃâ
  • brachial plexus avulsion pain
    »ó¿Ï ½Å°æÃÑ ÅëÁõ, »ó¿Ï ½Å°æÃÑ µ¿Åë
  • carotid plexus
    ¸ñµ¿¸Æ ½Å°æ ¾ó±â, °æµ¿¸Æ ½Å°æÃÑ
  • cavernous plexus
    ÇØ¸é Á¤¸Æ ¾ó±â, ÇØ¸é Á¤¸ÆÃÑ
  • celiac plexus
    º¹°­ ½Å°æ ¾ó±â, º¹°­ÃÑ
  • celiac plexus reflex
    º¹°­ ½Å°æÃÑ ¹Ý»ç
  • choroid plexus papilloma
    ¸Æ¶ôÃÑ À¯µÎÁ¾
  • common carotid plexus
    ¿Â¸ñ µ¿¸Æ ½Å°æ ¾ó±â, ÃÑ °æµ¿¸Æ ½Å°æÃÑ
  • cranial venous plexus
    ¸Ó¸® Á¤¸Æ ¾ó±â
  • enteric plexus
    Àå ½Å°æ ¾ó±â, ÀåÃÑ, Àå½Å°æÃÑ
  • esophageal plexus
    ½Äµµ ½Å°æÃÑ
  • external carotid plexus
    ¹Ù±ù¸ñ µ¿¸Æ ½Å°æ ¾ó±â, ¿Ü°æµ¿¸ÆÃÑ
  • fasciculus medialis plexus brachialis
    ¿Ï½Å°æÃÑ ³»Ãø ½Å°æ¼Ó
    ÇϽŰ氣 C8-T1ÀÇ ÀüÁö·Î ÀÌ·ç¾îÁö¸ç ¿©±â¼­ºÎÅÍ ³»Ãø Èä±Ù ½Å°æ, ³»Ãø »ó¿ÏÇÇ ½Å°æ, ³»Ãø Àü¿ÏÇÇ ½Å°æ, ô°ñ ½Å°æ ¹× Á¤Áß ½Å°æÀÇ ³»Ãø ½Å°æ±ÙÀÌ ³ª¿Â´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
molecular probes A group of atoms or molecules attached to other molecules or cellular structures and used in studying the properties of these molecules and structures. Radioactive DNA or RNA sequences are used in molecular genetics to detect the presence of a complementary sequence by molecular hybridization.
(12 Dec 1998)
molecular probe techniques The use of devices which use detector molecules to detect, investigate, or analyze other molecules, macromolecules, molecular aggregates, or organisms.
(12 Dec 1998)
molecular sequence data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as genbank, european molecular biology laboratory (embl), national biomedical research foundation (nbrf), or other sequence repositories.
(12 Dec 1998)
molecular sieve A gel-like material with pore sizes of such ranges as to exclude molecules above certain sizes; used in fractionating or purifying macromolecules.
(05 Mar 2000)
molecular structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number and location of chemical bonds.
(12 Dec 1998)
molecular weight The sum of the atomic weight's of all the atoms constituting a molecule; the mass of a molecule relative to the mass of a standard atom, now 12C (taken as 12.000). Relative molecular mass (Mr) is the mass relative to the dalton and has no units.
See: atomic weight.
Synonym: molecular mass, molecular weight ratio, relative molecular mass.
(05 Mar 2000)
molecular weight ratio The sum of the atomic weight's of all the atoms constituting a molecule; the mass of a molecule relative to the mass of a standard atom, now 12C (taken as 12.000). Relative molecular mass (Mr) is the mass relative to the dalton and has no units.
See: atomic weight.
Synonym: molecular mass, molecular weight ratio, relative molecular mass.
(05 Mar 2000)
heparin, low-molecular-weight <chemical> Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of haemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
Pharmacological action: anticoagulant, fibrinolytic agent.
(12 Dec 1998)
directed molecular evolution Techniques used to produce molecules exhibiting properties that conform to the demands of the experimenter.
(12 Dec 1998)
epidemiology, molecular The application of molecular biology to the answering of epidemiological questions. The examination of patterns of changes in DNA to implicate particular carcinogens and the use of molecular markers to predict which individuals are at highest risk for a disease are common examples.
(12 Dec 1998)
european molecular biology lab gene bank <molecular biology> A large database of DNA sequence data in Heidelberg, Germany, compiled from international sources. It is the European equivalent to the Genbank DNA sequence databank in the United States of America.
WWW: EMbase.
(09 Oct 1997)
evolution, molecular Evolution at the molecular level of DNA sequences and proteins. (rieger et al., glossary of genetics: classical and molecular, 5th ed)
(12 Dec 1998)
kinetic molecular theory <chemistry> This theory assumes that molecules must collide in order to react. The more collisions the more likely it is for a reaction to occur.
However, depending on the conditions, only a small fraction of the collisions are effective in producing a reaction. There are several constraints. In order for a reaction to occur, bonds initially are broken, which requires energy. This energy depends on the type of the reaction and comes from the kinetic energies that the molecules possess before the collision. It is called the activation energy. Increasing the temperature increases the kinetic energies and more collisions will occur. In adition, at a higher temperature a greater number of the reacting molecules might possess an energy equal to or greater than the activation energy. However the molecules must also collide in a specific orientation, called the steric factor in order for a reaction to occur.
A reaction will only be successful, if the collision has enough energy to be either equal to or greater than the activation energy and if the orientation of the collision allows for correct bond formation. These factors are in the Arrhenius equation: k = zp The rate constant k is proportional to the Arrhenius factor A. A is the product of the collision frequency z, and the steric factor p. The fraction of collisions with sufficient energy to produce a reaction are in the term of the equation.
(09 Jan 1998)
kininogen, high-molecular-weight A plasma protein, molecular weight of 110 kD, that normally exists in plasma in a 1:1 complex with prekallikrein. Hmwk is split by plasma kallikrein to produce bradykinin. The complex is a cofactor in the activation of coagulation factor xii. The product of this reaction, xiia, in turn activates prekallikrein to kallikrein.
(12 Dec 1998)
kininogen, low-molecular-weight A protein, molecular weight 50 kD, located in various normal tissues. Upon cleavage by kallikrein or other kallikreins, it forms kallidin. Kallidin, in turn, is converted into bradykinin.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á